Company news
Immix Biopharma, Inc. (NASDAQ:IMMX) news
Every Immix Biopharma, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
September 30, 2026
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
September 29, 2026
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
August 4, 2026
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
May 22, 2026
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
May 21, 2026
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
May 21, 2026
Immix Biopharma : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
May 7, 2026
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
April 9, 2026
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed, Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
March 31, 2026
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
March 29, 2026
Immix Biopharma to Participate in Upcoming Investor Conferences
March 3, 2026
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
January 28, 2026
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
December 9, 2025
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
December 7, 2025
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
December 7, 2025
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
November 12, 2025
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
November 3, 2025
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
October 14, 2025
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
October 6, 2025
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
October 1, 2025
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
September 18, 2025
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
September 11, 2025
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
September 8, 2025
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
August 25, 2025
Immix Biopharma Announces Other Serious Diseases Strategy
August 6, 2025
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
July 11, 2025
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
July 7, 2025
Immix Biopharma Attends FDA CEO Forum in Washington DC
June 6, 2025
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
June 3, 2025
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
May 23, 2025
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
May 22, 2025
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis
May 21, 2025
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
April 23, 2025
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
February 9, 2025
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
January 6, 2025
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
December 18, 2024
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
December 9, 2024
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
November 24, 2024
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
October 1, 2024
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
September 18, 2024
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
August 27, 2024
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
July 7, 2024
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
May 9, 2024
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
April 28, 2024
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
April 14, 2024
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
March 19, 2024
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
March 4, 2024
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
February 7, 2024
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
February 6, 2024
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
February 4, 2024